Contineum Therapeutics Finishes Enrollment for Phase 2 MS Trial

Contineum Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in neuroscience, inflammation, and immunology therapies, has announced a milestone in its development efforts. The company has successfully completed the targeted enrollment of 168 patients for its Phase 2 PIPE-307 VISTA trial, aimed at addressing relapsing-remitting multiple sclerosis (RRMS). This trial explores the potential of PIPE-307, an innovative M1 receptor antagonist, as a pioneering treatment option for RRMS.

The PIPE-307 VISTA trial is a Phase 2, randomized, double-blind, placebo-controlled, multi-center study designed to establish proof of concept. The primary objective is to evaluate the safety and efficacy of PIPE-307 in patients with RRMS. The trial will monitor various clinical and imaging endpoints that are indicative of changes in remyelination, which is a crucial aspect of RRMS treatment. Contineum expects that the last participant will complete the trial in the third quarter of 2025.

Stephen Huhn, Chief Medical Officer of Contineum Therapeutics, expressed satisfaction with reaching this significant milestone ahead of schedule. Huhn emphasized the importance of the trial in providing evidence for remyelination, which could position PIPE-307 as a groundbreaking and unique therapy for RRMS patients. He also expressed gratitude towards the trial's investigators, patients, and their families, and looked forward to sharing the initial data from the study.

Contineum Therapeutics is advancing PIPE-307 under a global license and development agreement with Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson. This partnership underscores the strategic importance of PIPE-307 in potentially redefining the treatment approach for RRMS.

In addition to PIPE-307, Contineum is actively developing multiple drug candidates for various conditions with unmet medical needs. The company is focused on creating novel, oral small molecule therapies that address significant gaps in treatment. Among these is PIPE-791, an LPA1 receptor antagonist being developed for idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain.

Contineum's commitment to advancing its drug candidates through clinical trials reflects its broader mission to address critical healthcare challenges within the fields of neuroscience, inflammation, and immunology. The PIPE-307 VISTA trial is a key component of this mission, as the company aims to deliver innovative therapeutic solutions that have the potential to improve patient outcomes significantly.

As Contineum moves forward with its clinical programs, the focus remains on achieving regulatory milestones and validating the therapeutic potential of its pipeline. The successful enrollment in the PIPE-307 VISTA trial marks an important step in this journey, bringing the company closer to its goal of introducing a novel treatment option for those affected by RRMS.

Overall, Contineum Therapeutics continues to position itself at the forefront of biopharmaceutical innovation, with a robust pipeline and strategic collaborations that enhance its capacity to develop impactful therapies for complex conditions. The progress in the PIPE-307 program exemplifies Contineum's dedication to scientific advancement and underscores its role as a key player in the evolving landscape of biopharmaceuticals.